Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.4.21.91: Flavivirin

This is an abbreviated version!
For detailed information about Flavivirin, go to the full flat file.

Word Map on EC 3.4.21.91

Reaction

Selective hydrolysis of -Xaa-Xaa-/-Yaa- bonds in which each of the Xaa can be either Arg or Lys and Yaa can be either Ser or Ala =

Synonyms

Dengue NS2b-NS3 protease, Dengue NS3 protease, dengue virus non-structural protein 3, dengue virus NS2B-NS3 protease, dengue virus protease, dengue virus serotype 2 protease, DENV NS2B-NS3, DENV-2 NS2B-NS3 protease, DENV2 NS2BNS3pro, DV2 NS2B/NS3pro, flavivirus NS2B-NS3 protease, non-structural protein 3 serine protease, non-structural protein NS2B-NS3 protease, nonstructural protein 3, NS2-3 protease, NS2B-3 proteinase, NS2B-NS3 complex, NS2B-NS3 protease, NS2B-NS3 protease-helicase, NS2B-NS3 proteinase, NS2B-NS3 proteolytic complex, NS2B-NS3 serine protease, NS2B-NS3 serine proteinase, NS2B-NS3(pro)teinase, NS2b-NS3-protease, NS2B-NS3p, NS2B-NS3pro, NS2B/3 protease, NS2B/NS3, NS2B/NS3 complex, NS2B/NS3 protease, NS2B/NS3 protease complex, NS2B/NS3 proteinase, NS2B/NS3 serine protease, NS2B/NS3pro serine protease, NS2B18NS3, NS2BNS3(pro)tease, NS3, NS3 protease, NS3 proteinase, NS3 serine protease, NS3pro, two-component NS2B-NS3 protease, viral serine protease NS2B/NS3, WNV NS2B-NS3, Yellow fever virus (flavivirus) protease, yellow fever virus NS2B-NS3-181 protease, YFV NS2B/NS3 protease, Zika protease, Zika virus NS2B-NS3 protease, ZIKV NS2B/NS3 protease, ZIKV protease

ECTree

     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.21 Serine endopeptidases
                3.4.21.91 Flavivirin

Inhibitors

Inhibitors on EC 3.4.21.91 - Flavivirin

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1'R,2R,4'S,6S,8'R,10'E,12'S,14'E,16'E,21'R)-6-[(2S)-butan-2-yl]-12'-[[(2R,4S,5R,6R)-5-[[(2S,4S,5R,6S)-4,5-dihydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy]-4,6-dihydroxytetrahydro-2H-pyran-2-yl]oxy]-21',24'-dihydroxy-11',22'-dimethyl-3,4,5,6-tetrahydro-2'H-spiro[pyran-2,6'-[3,7,19]trioxatetracyclo[15.6.1.14,8.020,24]pentacosa[10,14,16,22]tetraen]-2'-one
-
-
(2aE,4E,5'S,6S,6'S,7S,8E,11R,13S,15S,17aS,20Z,20aR)-6'-cyclohexyl-20b-hydroxy-5',6,8,11,19-pentamethyl-20-(methylimino)-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine
-
-
(2S)-4-[3-(aminomethyl)phenyl]-2-([(2S)-4-[3-(aminomethyl)phenyl]-2-[(phenylacetyl)amino]butanoyl]amino)-N-[(trans-4-carbamimidamidocyclohexyl)methyl]butanamide
(2S)-4-[4-(aminomethyl)phenyl]-2-([(2S)-4-[4-(aminomethyl)phenyl]-2-[(phenylacetyl)amino]butanoyl]amino)-N-[(trans-4-carbamimidamidocyclohexyl)methyl]butanamide
(2S)-N-[(trans-4-carbamimidamidocyclohexyl)methyl]-4-[3-(carbamimidamidomethyl)phenyl]-2-([(2S)-4-[3-(carbamimidamidomethyl)phenyl]-2-[(phenylacetyl)amino]butanoyl]amino)butanamide
(2S)-N-[(trans-4-carbamimidamidocyclohexyl)methyl]-4-[4-(carbamimidamidomethyl)phenyl]-2-([(2S)-4-[4-(carbamimidamidomethyl)phenyl]-2-[(phenylacetyl)amino]butanoyl]amino)butanamide
(3R,7aS)-2,3-bis(4-nitrophenyl)hexahydro-1H-pyrrolo-[1,2-c]imidazol-1-one
-
crystal structure analysis
(3R,7aS)-2-(4-nitrophenyl)-3-(4-(trifluoromethyl)-phenyl)-hexahydro-1H- pyrrolo[1,2-c]-imidazol-1-one
-
below 50% inhibition
(3R,7aS)-2-(4-nitrophenyl)-3-phenylhexahydro-1H-pyrrolo[1,2-c]imidazol-1-one
-
67% inhibition
(3R,7aS)-3-(3-nitrophenyl)-2-(4-nitrophenyl)hexahydro-1H-pyrrolo[1,2-c]imidazol-1-one
-
below 50% inhibition
(3R,7aS)-3-(4-chlorophenyl)-2-(4-nitrophenyl)hexahydro-1H-pyrrolo[1,2-c]-imidazol-1-one
-
below 50% inhibition, crystal structure analysis
(3R,7aS)-3-(4-isopropylphenyl)-2-(4-nitrophenyl)-hexahydro-1H-pyrrolo[1,2-c]imidazol-1-one
-
below 50% inhibition
(3R,7aS)-3-(4-methoxyphenyl)-2-(4-nitrophenyl)hexahydro-1H-pyrrolo[1,2-c]imidazol-1-one
-
below 50% inhibition
(3R,7aS)-3-(4-nitrobenzyl)-2-(4-nitrophenyl)hexahydro-1Hpyrrolo[1,2-c]-imidaz-ol-1-one
-
below 50% inhibition
(3R,7aS)-3-benzyl-2-(4-nitrophenyl)hexahydro-1H-pyrrolo[1,2-c]imidazol-1-one
-
42% inhibition
(3R,7aS)-3-ethyl-2-(4-nitrophenyl)hexahydro-1H-pyrrolo[1,2-c]imidazol-1-one
-
60% inhibition
(3R,7aS)-3-isopropyl-2-(4-nitrophenyl)hexahydro-1H-pyrrolo[1,2-c]imidazol-1-one
-
34% inhibition
(3R,7aS)-3-methyl-2-(4-nitrophenyl)hexahydro-1H-pyrrolo[1,2-c]imidazol-1-one
-
42% inhibition
(3S,7aS)-2,3-bis(4-nitrophenyl)hexahydro-1H-pyrrolo-[1,2-c]imidazol-1-one
-
below 50% inhibition
(3S,7aS)-2-(4-nitrophenyl)-3-(4-(trifluoromethyl)-phenyl)hexahydro-1H- pyrrolo[1,2-c]-imidazol-1-one
-
below 50% inhibition
(3S,7aS)-3-(4-chlorophenyl)-2-(4-nitrophenyl)hexa-hydro-1H-pyrrolo[1,2-c]imidazol-1-one
-
below 50% inhibition
(5-amino-1-phenylsulfonylpyrazol-3-yl) 2-bromobenzoate
-
100.8% inhibition at 0.05 mM
(5-amino-1-phenylsulfonylpyrazol-3-yl)thiophene-2-carboxylate
-
101.4% inhibition at 0.05 mM
(E)-N-(5-(benzylsulfanyl)-1,3,4-thiadiazol-2-yl)-2-cyano-3-(1-((2-cyanophenyl)methyl)-1H-indol-3-yl)prop-2-enamide
-
-
(E)-N-(5-(benzylsulfanyl)-1,3,4-thiadiazol-2-yl)-2-cyano-3-(1-((2-fluorophenyl)methyl)-1H-indol-3-yl)prop-2-enamide
-
-
(E)-N-(5-(benzylsulfanyl)-1,3,4-thiadiazol-2-yl)-2-cyano-3-(1-((4-fluorophenyl)methyl)-1H-indol-3-yl)prop-2-enamide
-
-
(S)-2-(4-nitrophenyl)hexahydro-1H-pyrrolo[1,2-c]imida-zol-1-one
-
39% inhibition
(S)-2-acetamido-6-amino-N-((S)-5-guanidino-1-oxopentan-2-yl)hexanamide
-
inhibitor-enzyme interaction analysis, crystal structure analysis of the complex, NMR spectrometry, overview
1,10-phenanthroline
-
zinc-selective chelator, inhibits NS2/3 auto-cleavage and NS3 protease activity
1-(2,6-difluorophenyl)-2-[1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl]ethanol
-
-
1-(2,6-difluorophenyl)-2-[1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl]ethanone
-
-
1-(2-fluorophenyl)-2-[1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl]ethanone
-
-
1-(3-[[2-(1H-benzimidazol-2-yl)hydrazinyl]methyl]-4-hydroxy-5-[(E)-[2-(3H-indol-2-yl)hydrazinylidene]methyl]phenyl)butane-1,2-dione
-
-
1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl 2,6-difluoro-3-methylbenzoate
-
-
1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl 2,6-difluorobenzoate
-
-
1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl benzoate
-
-
1-(4-[3-[4-(furan-3-yl)phenyl]-5-(piperidin-4-ylmethoxy)pyrazin-2-yl]phenyl)methanamine
1-benzyl-3-methyl-1H-pyrazol-5-yl 2,6-difluoro-3-methylbenzoate
-
-
1-benzyl-3-methyl-1H-pyrazol-5-yl 2,6-difluorobenzoate
-
-
1-[(4-[2-[5-(4-fluorophenyl)-3-(thiophen-2-yl)-4,5-dihydro-1H-pyrazol-1-yl]-1,3-thiazol-4-yl]phenyl)sulfonyl]piperidine
-
-
1-[5-[(4-chloro-5-methyl-3-nitro-1H-pyrazol-1-yl)methyl]furan-2-yl]-2-[1-[2-(diethylamino)ethyl]-1H-benzimidazol-2-yl]ethanone
-
-
2,6-difluoro-benzoyl-Nle-Lys-Arg-Arg-CF3-ketone
-
-
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
-
-
2-([[3,6-bis(2,6-dimethylphenyl)-7-oxo-2-thioxo-2,3,6,7-tetrahydro[1,3]thiazolo[4,5-d]pyrimidin-5-yl]sulfanyl]methyl)-7-chloro-4H-pyrido[1,2-a]pyrimidin-4-one
-
-
2-benzyl-N-[2-methyl-4-(4-methylpiperazin-1-yl)phenyl]-1,2,3,4-tetrahydrobenzo[b][1,6]naphthyridine-10-carboxamide
-
compound identified by a pharmacophore model based on X-ray crystal structure and predicted binding patterns. Compound shows good cell-based bioactivity
2-naphthoyl-Lys-Arg-Arg
2-[(E)-[2-(3-bromophenyl)hydrazinylidene]methyl]-N'-[(1E)-2-phenylethylidene]quinoline-4-carbohydrazide
-
-
2-[1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl]-1-phenylethanol
-
-
2-[1-(4-methoxybenzyl)-3-methyl-1H-pyrazol-5-yl]-1-phenylethanone
-
-
2-[1-(5-methyl-1,3,4-oxadiazol-2-yl)ethyl]-1,2-benzothiazol-3(2H)-one
-
-
2-[[(4-methoxyphenyl)amino]methylidene]cyclohexane-1,3-dione
-
56% inhibition at 0.05 mM
3-[(8-benzoyl-1-methyl[1,2,4]triazolo[4,3-a]quinoxalin-4-yl)amino]benzoic acid
-
-
3-[[6-(3-fluorophenyl)pyridazin-3-yl]amino]-N-[2-(piperidin-1-yl)ethyl]benzamide
-
-
4-(aminomethyl)-Nalpha-benzoyl-N-[(1R)-4-carbamimidamido-1-(dihydroxyboranyl)butyl]-L-phenylalaninamide
cn-716, ZIKV protease in complex with a peptidomimetic boronic acid inhibitor reveals a cyclic diester between the boronic acid and glycerol, enzyme binding structure, binds to the active site, crystal structure analysis, detailed overview
4-(guanidinomethyl)-phenylacetyl-Lys-Lys-Arg-NH2
4-aminobenzoyl-Lys-Arg-Arg
4-aminobenzoyl-Lys-Lys-Arg
4-aminophenylacetyl-Lys-Arg-Arg
4-guanidino-benzoic acid 4-nitrophenyl ester
-
the fold of Dengue NS2B-NS3pro in solution with and without bound inhibitor by nuclear magnetic resonance spectroscopy is analyzed. Multiple paramagnetic lanthanide tags are attached to different sites to generate pseudocontact shifts (PCS). The PCSs show, that in the presence of a positively charged low-molecular weight inhibitor, the enzyme assumes a closed state that is very similar to the closed state previously observed for the West Nile virus protease. To assess the open state, a binding site for a Gd3+ complex is created and paramagnetic relaxation enhancements is measured. The results show that the specific open conformation displayed in the crystal of DEN NS2B-NS3pro is barely populated in solution
4-hydroxypanduratin
-
-
4-hydroxypanduratin A
-
cyclohexenyl chalcone derivative, competetive inhibitor, compound from Boesenbergia rotunda (L.) Mansf. Kulturpfl.
4-methylumbelliferyl-alpha-D-mannopyranoside
-
i.e. compound 4282211 of ZINC database, identified by molecular docking. Inhibitor can efficiently bind to the NS2b/NS3 protease without changing the conformation of the protein, most active inhibitor identified, acitve against serotypes DENV1, DENV2, DENV3
4-phenylphenylacetyl-Lys-Arg-Arg
4-phenylphenylacetyl-Lys-Lys-Arg
4-[3-acetyl-5-(2-phenylquinolin-4-yl)-2,3-dihydro-1,3,4-oxadiazol-2-yl]benzoic acid
4-[[3-(azepan-1-yl)-6-oxo-6H-anthra[1,9-cd][1,2]oxazol-5-yl]amino]butanoic acid
-
-
5,6-dichloro-2H-triazolo[4,5-b]pyrazine
NSC157058, the inhibitor decreases ZIKV infection in mice
5-amino-1-((4-methoxyphenyl)sulfonyl)-1H-pyrazol-3-ol
-
-
5-amino-1-((4-methoxyphenyl)sulfonyl)-1H-pyrazol-3-yl benzoate
-
the benzoyl moiety of the inhibitor forms a covalent bond with the side chain of S135. Structure and dynamics of bZiPro-inhibitor complex in solution
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2,3,4-trifluorobenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2,3,5,6-tetrafluoro-4-methylbenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2,3,6-trifluorobenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2,4,5-trifluorobenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2,4,6-trifluorobenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2,4-difluorobenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2,5-difluorobenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2,6-dichlorobenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2,6-difluoro-3-methylbenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2,6-difluorobenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2-ethoxybenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2-fluoro-3-(trifluoromethyl)benzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2-methylbenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 2-nitrobenzoate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl 3-chlorothiophene-2-carboxylate
-
-
5-amino-1-[(4-methoxyphenyl)sulfonyl]-1H-pyrazol-3-yl thiophene-3-carboxylate
-
-
5-methyl-2-[4-[(4-[[4-(4-methyl-4,5-dihydro-1H-imidazol-3-ium-2-yl)phenyl]amino]-4a,8a-dihydrophthalazin-1-yl)amino]phenyl]-4,5-dihydro-1H-imidazol-3-ium
-
-
5-[(4-chloro-3-nitro-1H-pyrazol-1-yl)methyl]-N-[1-[2-(diethylamino)ethyl]-1H-benzimidazol-2-yl]furan-2-carboxamide
-
-
5-[(E)-2-(2,6-difluorophenyl)ethenyl]-1-(4-methoxybenzyl)-3-methyl-1H-pyrazole
-
-
6-(4-chlorophenyl)-3-[[3-[[6-(4-chlorophenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazol-3-yl]methoxy]phenoxy]methyl]-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole
NSC716903
6-methoxy-3-methyl-1H-benzo[de]cinnoline
-
98.2% inhibition at 0.05 mM
7-[(1,3-benzothiazol-2-ylamino)(2-hydroxyphenyl)methyl]quinolin-8-ol
-
-
7-[(1,3-benzothiazol-2-ylamino)(phenyl)methyl]quinolin-8-ol
-
-
7-[(3-hydroxyphenyl)(1,3-thiazol-2-ylamino)methyl]quinolin-8-ol
-
-
7-[1-(methylamino)ethyl]quinolin-8-ol
-
-
Ac-EVKKQR-NH2
-
-
Ac-FAAGRK-NH2
-
-
Ac-GKR-NH2
-
-
Ac-KKR-NH2
-
-
Ac-KR-NH2
-
-
Ac-RTSKKR-NH2
-
-
Ac-SKKR-NH2
-
-
Ac-TTSTRR-NH2
-
-
acetyl-Ala-Arg-agmatine
acetyl-Ala-Lys-agmatine
acetyl-Arg-Lys-agmatine
acetyl-K-agmatine
-
acetyl-K-agmatine is weakly bound by the ZIKV protease and does inhibit the enzyme. The Arg and Lys residues of acyl-KR-COOH occupy the S1 and S2 sites of the protease, respectively
acetyl-Lys-Arg-Arg
acetyl-Lys-Lys-agmatine
acetyl-Lys-Lys-Arg
acetyl-Trp-Lys-agmatine
AcKR-H
-
-
agathisflavone
-
binds to a specific allosteric binding site of the enzyme
alpinetin
-
compound from Boesenbergia rotunda (L.) Mansf. Kulturpfl.
antibody D05320
-
-
-
antibody D05321
-
-
-
antibody D05322
-
-
-
antibody D05323
-
-
-
antibody D05444
-
-
-
antibody D05445
-
-
-
antibody D05446
-
-
-
Aprotinin
benzoyl-Lys-Lys(acetyl)-Arg
benzoyl-Lys-Lys(benzoyl)-Arg
benzoyl-Lys-Lys(benzyl)-Arg
benzoyl-Lys-Lys(p-anisoyl)-Arg
benzoyl-Lys-Lys-Arg
benzoyl-Nle-KRR
homology model of the DV2 NS2B/NS3pro complexed with the peptidic inhibitor based on West nile virus structure
benzoyl-Nle-Lys-Arg-Arg
benzoyl-Nle-Lys-Arg-Arg-B(OH)2
-
dynamics of NS2B and NS3pro in the presence of the peptidic inhibitor
benzoyl-Nle-Lys-Thr-Arg-H
-
-
Bovine pancreatic trypsin inhibitor
-
Bowman-Birk inhibitor
-
from mung bean
Bz-Ala-Lys-Arg-Arg
-
-
Bz-Ala-Lys-Arg-Arg-H
-
-
Bz-Arg-Arg
-
-
Bz-Arg-Arg-H
-
-
Bz-D-Nle-Lys-Arg-Arg-H
-
-
Bz-Lys-Arg-Arg
-
-
Bz-Lys-Arg-Arg-H
-
-
Bz-N-Me-Nle-Lys-Arg-Arg-H
-
-
Bz-Nle-(3-amino)-Phe-(3-imino)-Phe-(3,4-dimethoxy)-Phe
-
-
Bz-Nle-(3-guanidino)-Phe-(4-guanidino)-Phe-(4-guanidino)-Phe
-
-
Bz-Nle-(4-amino)-Phe-(3-guanidino)-Phe-(4-amino)-Phe
-
-
Bz-Nle-(4-amino)-Phe-(3-guanidino)-Phe-Arg
-
-
Bz-Nle-(4-amino)-Phe-(3-imino)-Phe-Arg
-
-
Bz-Nle-(4-amino)-Phe-(4-guanidino)-Phe-Trp
-
-
Bz-Nle-Ala-Arg-Arg
-
-
Bz-Nle-Ala-Arg-Arg-H
-
-
Bz-Nle-Arg-(3-guanidino)-Phe-(4-amino)-Phe
-
-
Bz-Nle-D-Lys-Arg-Arg-H
-
-
Bz-Nle-His-(3-guanidino)-Phe-(4-guanidino)-Phe
-
-
Bz-Nle-His-(3-guanidino)-Phe-beta-(2-naphthyl)-Ala
-
-
Bz-Nle-His-(3-imino)-Phe-Arg
-
-
Bz-Nle-His-(4-guanidino)-Phe-(4-guanidino)-Phe
-
-
Bz-Nle-His-(4-guanidino)-Phe-Trp
-
-
Bz-Nle-homo-His-(3-guanidino)-Phe-(4-guanidino)-Phe
-
-
Bz-Nle-homoHis-(3-guanidino)-Phe-Arg
-
-
Bz-Nle-homoHis-(4-guanidino)-Phe-(4-phenyl)-Phe
-
-
Bz-Nle-Lys-Ala-Arg
-
-
Bz-Nle-Lys-Ala-Arg-H
-
-
Bz-Nle-Lys-Arg-(p-Cl)Phe-H
-
-
Bz-Nle-Lys-Arg-(p-CN)Phe-H
-
-
Bz-Nle-Lys-Arg-(p-guanidinyl)Phe-H
-
-
Bz-Nle-Lys-Arg-(p-Me)Phe-H
-
-
Bz-Nle-Lys-Arg-(p-Ph)Phe-H
-
-
Bz-Nle-Lys-Arg-Ala
-
-
Bz-Nle-Lys-Arg-Ala-H
-
-
Bz-Nle-Lys-Arg-Arg
-
-
Bz-Nle-Lys-Arg-Arg(OH)-CONH-Bn
-
-
Bz-Nle-Lys-Arg-Arg-B(OH)2
-
-
Bz-Nle-Lys-Arg-Arg-benzoxazole
-
-
Bz-Nle-Lys-Arg-Arg-CF3
-
-
Bz-Nle-Lys-Arg-Arg-H
-
-
Bz-Nle-Lys-Arg-Arg-NH2
-
-
Bz-Nle-Lys-Arg-Arg-NHSO2CF3
-
-
Bz-Nle-Lys-Arg-Arg-OH
-
-
Bz-Nle-Lys-Arg-Arg-thiazole
-
-
Bz-Nle-Lys-Arg-D-Arg-H
-
-
Bz-Nle-Lys-Arg-homoPhe-H
-
-
Bz-Nle-Lys-Arg-Lys
-
-
Bz-Nle-Lys-Arg-Lys-H
-
-
Bz-Nle-Lys-Arg-Phe
-
-
Bz-Nle-Lys-Arg-Phe-H
-
-
Bz-Nle-Lys-Arg-Phg-H
-
-
Bz-Nle-Lys-Arg-Trp
-
-
Bz-Nle-Lys-Arg-Trp-H
-
-
Bz-Nle-Lys-D-Arg-Arg-H
-
-
Bz-Nle-Lys-Lys-Arg
-
-
Bz-Nle-Lys-Lys-Arg-B(OH)2
-
-
Bz-Nle-Lys-Lys-Arg-H
-
-
Bz-Nle-Lys-N-Me-Arg-Arg-H
-
-
Bz-Nle-Lys-Phe-Arg
-
-
Bz-Nle-Lys-Phe-Arg-H
-
-
Bz-Nle-Lys-Pro-Arg-H
-
-
Bz-Nle-Lys-Thr-Arg-H
-
-
Bz-Nle-Lys-Thr-Arg-NH2
-
-
Bz-Nle-Lys-Thr-Arg-OH
-
-
Bz-Nle-N-Me-Lys-Arg-Arg-H
-
-
Bz-Nle-Phe-Arg-Arg
-
-
Bz-Nle-Phe-Arg-Arg-H
-
-
Bz-Nle-Pro-Arg-Arg-H
-
-
Bz-Phe-Lys-Arg-Arg
-
-
Bz-Phe-Lys-Arg-Arg-H
-
-
CaCl2
-
strongly inhibits
cardamonin
-
chalcone, non-competetive inhibitor, compound from Boesenbergia rotunda (L.) Mansf. Kulturpfl.
Cbz-Lys-Arg-(4-GuPhe)P(OPh)2
-
-
Cbz-Lys-Arg-(4-GuPhg)P(OPh)2
-
-
Cbz-Lys-Arg-Arg
-
-
Cbz-Lys-Arg-ArgP(OPh)2
-
-
Cbz-Lys-Arg-LysP(OPh)2
-
-
cinnamoyl-Lys-Arg-Arg
cyclo(D-arginyl-L-arginyl-L-arginyl-L-lysyl-L-seryl-4-phenyl-L-phenylalanyl-L-seryl-D-arginyl)
-
-
cyclo(D-arginyl-L-arginyl-L-arginyl-L-lysyl-L-seryl-4-phenyl-L-phenylalanyl-L-seryl-D-phenylalanyl)
-
-
cyclo(L-alanylglycyl-L-alanyl-L-arginyl-L-lysyl-L-serylglycyl-L-cysteinyl)
-
-
cyclo(L-alanylglycyl-L-lysyl-L-alanyl-L-lysyl-L-serylglycyl-L-cysteinyl)
-
-
cyclo(L-alanylglycyl-L-lysyl-L-arginyl-L-alanyl-L-serylglycyl-L-cysteinyl)
-
-
cyclo(L-alanylglycyl-L-lysyl-L-arginyl-L-lysyl-L-alanylglycyl-L-cysteinyl)
-
-
cyclo(L-alanylglycyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-L-phenylalanyl-L-cysteinyl)
-
-
cyclo(L-alanylglycyl-L-lysyl-L-arginyl-L-lysyl-L-serylglycyl-L-alanyl)
-
-
cyclo(L-alanylglycyl-L-lysyl-L-arginyl-L-lysyl-L-serylglycyl-L-cysteinyl)
-
-
cyclo(L-arginyl-L-lysyl-L-seryl-4-phenyl-L-phenylalanyl-L-seryl-D-phenylalanyl-D-prolyl-L-arginyl)
-
-
cyclo(L-arginyl-L-lysyl-L-seryl-4-phenyl-L-phenylalanyl-L-seryl-D-phenylalanyl-D-prolyl-L-lysyl)
-
-
cyclo-[L-Pro-L-Phe-L-Leu-L-Lys-Gly-L-Val-L-Tyr-L-Glu-L-Asp-L-Phe-L-Phe-Gly]
-
-
cyclopropionyl-Lys-Lys-Arg
cyclo[3-(1-naphthyl)-L-alanyl-D-phenylalanyl-D-arginyl-L-arginyl-L-arginyl-L-lysyl-L-alanyl-(2S)-2-amino-4-phenylbutanoyl]
-
-
cyclo[3-(1-naphthyl)-L-alanyl-D-phenylalanyl-D-arginyl-L-arginyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl]
-
-
cyclo[3-(1-naphthyl)-L-alanyl-D-phenylalanyl-D-arginyl-L-arginyl-L-arginyl-L-lysyl-N6-[CH2NH]-L-alanyl-(2S)-2-amino-4-phenylbutanoyl]
-
-
cyclo[3-(2-naphthyl)-D-alanyl-D-arginyl-L-arginyl-L-arginyl-L-lysyl-3-(2-naphthyl)-D-alanyl-(2S)-2-amino-4-phenylbutanoyl-L-phenylalanyl]
-
-
cyclo[3-(2-naphthyl)-D-alanyl-D-arginyl-L-arginyl-L-arginyl-L-lysyl-D-phenylalanyl-(2S)-2-amino-4-phenylbutanoyl-L-phenylalanyl]
-
-
cyclo[3-(2-naphthyl)-L-alanyl-D-phenylalanyl-D-arginyl-L-arginyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl]
-
-
cyclo[3-(2-naphthyl)-L-alanyl-L-seryl-D-phenylalanyl-D-prolyl-L-lysyl-L-arginyl-L-lysyl-L-seryl]
-
-
cyclo[D-alanyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl-L-seryl-D-phenylalanyl]
-
-
cyclo[L-alany-(2R)-2-phenylglycyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl]
-
-
cyclo[L-alany-(2S)-2-phenylglycyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl]
-
-
cyclo[L-alanyl-(2R)-2-amino-4-phenylbutanoylglycyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl]
-
-
cyclo[L-alanyl-(2S)-2-amino-4-phenylbutanoylglycyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl]
-
-
cyclo[L-alanyl-D-phenylalanylglycyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl]
-
-
cyclo[L-alanyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl-L-seryl-D-phenylalanyl]
-
-
cyclo[L-alanyl-L-phenylalanylglycyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl]
-
-
cyclo[L-alanylglycyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-(2R)-2-amino-4-phenylbutanoyl-L-cysteinyl]
-
-
cyclo[L-alanylglycyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl-L-alanyl]
-
-
cyclo[L-alanylglycyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl-L-cysteinyl]
-
-
cyclo[L-alanylglycyl-L-lysyl-L-arginyl-L-lysyl-L-seryl-(2S)-2-phenylglycyl-L-cysteinyl]
-
-
cyclo[L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl-L-seryl-D-phenylalanyl-D-prolyl-L-lysyl]
-
-
cyclo[L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl-L-seryl-D-phenylalanyl-L-prolyl-L-lysyl]
-
-
cyclo[L-arginyl-L-lysyl-L-seryl-(2S)-2-amino-4-phenylbutanoyl-L-seryl-D-phenylalanylglycyl-L-lysyl]
-
-
D-methionyl-N-(4-nitrobenzyl)-L-prolinamide
-
64% inhibition
D-methionyl-N-benzyl-L-prolinamide
-
42% inhibition
D-methionyl-N-phenyl-L-prolinamide
-
below 50% inhibition
decanoyl-Arg-Val-Lys-Arg-chloromethylketone
-
completely inhibits autolysis of the NS2B-NS3pro construct
diphenyl (1-[[(benzyloxy)carbonyl]amino]-3-carbamimidamidopropyl)phosphonate
-
-
diphenyl (1-[[(benzyloxy)carbonyl]amino]-4-carbamimidamidobutyl)phosphonate
-
12% inhibition
diphenyl (3-amino-1-[[(benzyloxy)carbonyl]amino]-3-oxopropyl)phosphonate
-
15% inhibition
diphenyl (3-amino-1-[[(benzyloxy)carbonyl]amino]propyl)phosphonate
-
12% inhibition
diphenyl (5-amino-1-[[(benzyloxy)carbonyl]amino]pentyl)phosphonate
-
-
diphenyl ([4-(1H-benzimidazol-1-yl)phenyl][[(benzyloxy)carbonyl]amino]methyl)phosphonate
-
4% inhibition
diphenyl ([[(benzyloxy)carbonyl]amino][4-(1H-pyrazol-1-yl)phenyl]methyl)phosphonate
-
5% inhibition
diphenyl ([[(benzyloxy)carbonyl]amino][4-(4-methylpiperazin-1-yl)phenyl]methyl)phosphonate
-
3% inhibition
diphenyl ([[(benzyloxy)carbonyl]amino][4-(morpholin-4-yl)phenyl]methyl)phosphonate
-
1% inhibition
diphenyl [(3-aminophenyl)[[(benzyloxy)carbonyl]amino]methyl]phosphonate
-
8% inhibition
diphenyl [(4-aminophenyl)[[(benzyloxy)carbonyl]amino]methyl]phosphonate
-
16% inhibition
diphenyl [1-[[(benzyloxy)carbonyl]amino]-3-(carbamimidoylsulfanyl)propyl]phosphonate
-
22% inhibition
diphenyl [2-(4-aminophenyl)-1-[[(benzyloxy)carbonyl]amino]ethyl]phosphonate
diphenyl [[[(benzyloxy)carbonyl]amino](3-carbamimidamidophenyl)methyl]phosphonate
-
11% inhibition
diphenyl [[[(benzyloxy)carbonyl]amino](3-nitrophenyl)methyl]phosphonate
-
4% inhibition
diphenyl [[[(benzyloxy)carbonyl]amino](4-carbamimidamidophenyl)methyl]phosphonate
-
-
diphenyl [[[(benzyloxy)carbonyl]amino](4-carbamimidoylphenyl)methyl]phosphonate
-
22% inhibition
diphenyl [[[(benzyloxy)carbonyl]amino](4-cyanophenyl)methyl]phosphonate
-
8% inhibition
diphenyl [[[(benzyloxy)carbonyl]amino](4-nitrophenyl)methyl]phosphonate
-
3% inhibition
diphenyl [[[(benzyloxy)carbonyl]amino](6-carbamimidoylnaphthalen-2-yl)methyl]phosphonate
-
12% inhibition
diphenyl [[[(benzyloxy)carbonyl]amino](6-cyanonaphthalen-2-yl)methyl]phosphonate
-
2% inhibition
diphenyl [[[(benzyloxy)carbonyl]amino](carbamimidamido)methyl]phosphonate
-
-
EDTA
-
zinc-selective chelator, inhibits NS2/3 auto-cleavage and NS3 protease activity
L-methionyl-N-(4-nitrophenyl)-L-prolinamide
-
68% inhibition
myricetin
-
binds to a specific allosteric binding site of the enzyme
N'-(2-ethylhexyl)-N'-(6-[N'-[N-(3-methylheptan-2-yl)carbamimidoyl]carbamimidamido]hexyl)imidodicarbonimidic diamide (non-preferred name)
-
-
N-(6-nitro-2,3-dihydro-1,3-benzothiazol-2-yl)-2-([4-(trifluoromethyl)phenyl]sulfanyl)benzamide
-
EC50 value 0.1 microM
N-(6-nitro-2,3-dihydro-1,3-benzothiazol-2-yl)-3-[(4-nitrophenyl)sulfanyl]benzamide
-
EC50 value 0.3 microM
N-(9-ethylcarbazol-3-yl)-2-[(4-ethyl-5-furan-2-yl-1,2,4-triazol-3-yl)sulfanyl]acetamide
-
68.8% inhibition at 0.05 mM
N-benzyl-N,N-dimethyl-2-[2-[4-(2,2,3-trimethylpentan-3-yl)phenoxy]ethoxy]ethanaminium
-
-
N-[(2S)-1-[[(trans-4-carbamimidamidocyclohexyl)methyl]amino]-4-(4-carbamimidamidophenyl)-1-oxobutan-2-yl]-N2-(phenylacetyl)-L-lysinamide
N-[(2S)-1-[[(trans-4-carbamimidamidocyclohexyl)methyl]amino]-4-[3-(carbamimidamidomethyl)cyclohexa-1,5-dien-1-yl]-1-oxobutan-2-yl]-N2-(phenylacetyl)-L-lysinamide
N-[(2S)-1-[[(trans-4-carbamimidamidocyclohexyl)methyl]amino]-4-[4-(carbamimidamidomethyl)phenyl]-1-oxobutan-2-yl]-N2-(phenylacetyl)-L-lysinamide
N-[(2S)-4-[3-(aminomethyl)phenyl]-1-[[(trans-4-carbamimidamidocyclohexyl)methyl]amino]-1-oxobutan-2-yl]-N2-(phenylacetyl)-L-lysinamide
N-[(2S)-4-[4-(aminomethyl)phenyl]-1-[[(trans-4-carbamimidamidocyclohexyl)methyl]amino]-1-oxobutan-2-yl]-N2-(phenylacetyl)-L-ornithinamide
N-[(2S)-6-amino-1-([(2S)-6-amino-1-[(3R)-3-(carbamimidamidomethyl)pyrrolidin-1-yl]-1-oxohexan-2-yl]amino)-1-oxohexan-2-yl]-2-(biphenyl-4-yl)acetamide
-
-
N-[(2S)-6-amino-1-([(2S)-6-amino-1-[(3S)-3-(carbamimidamidomethyl)pyrrolidin-1-yl]-1-oxohexan-2-yl]amino)-1-oxohexan-2-yl]-2-(biphenyl-4-yl)acetamide
-
-
N-[(2S)-6-amino-1-([(2S)-6-amino-1-[4-(carbamimidamidomethyl)piperidin-1-yl]-1-oxohexan-2-yl]amino)-1-oxohexan-2-yl]-2-(biphenyl-4-yl)acetamide
-
-
N-[(trans-4-carbamimidamidocyclohexyl)methyl]-N2-[(2S)-4-(3-carbamimidamidophenyl)-2-[(phenylacetyl)amino]butanoyl]-L-lysinamide
N-[(trans-4-carbamimidamidocyclohexyl)methyl]-N2-[(2S)-4-[3-(carbamimidamidomethyl)phenyl]-2-[(phenylacetyl)amino]butanoyl]-L-lysinamide
N-[(trans-4-carbamimidamidocyclohexyl)methyl]-N2-[(2S)-4-[4-(carbamimidamidomethyl)phenyl]-2-[(phenylacetyl)amino]butanoyl]-L-lysinamide
N-[4-[5-(4-acetamidophenyl)pentyl]phenyl]acetamide
NSC86414
N2-(1,3-benzodioxol-5-ylacetyl)-L-lysyl-L-lysinamide
N2-(1,3-thiazol-2-yl)-L-arginyl-N-[(1S)-2-amino-2-oxo-1-(4-[[4-(trifluoromethyl)benzyl]oxy]phenyl)ethyl]-L-lysinamide
-
-
N2-(4-[(Z)-[3-(cyclohexylmethyl)-2,4-dioxo-1,3-thiazolidin-5-ylidene]methyl]benzoyl)-L-lysyl-N-[(1S)-2-amino-2-oxo-1-phenylethyl]-L-lysinamide
-
-
N2-(adamant-1-yl(amino)acetyl)-L-lysyl-L-lysinamide
N2-(adamant-1-ylacetyl)-L-lysyl-L-lysinamide
N2-(biphenyl-3-ylacetyl)-L-lysyl-N-[(1-carbamimidoylpiperidin-4-yl)methyl]-L-lysinamide
-
C-terminal agmatine peptidomimetic inhibitor, competitive
N2-(biphenyl-4-ylacetyl)-L-lysyl-L-Lys-L-Arg-aldehyde
-
-
N2-(biphenyl-4-ylacetyl)-L-lysyl-L-lysinamide
N2-(biphenyl-4-ylacetyl)-L-lysyl-N-(4-carbamimidamidobutyl)-L-lysinamide
-
-
N2-(biphenyl-4-ylacetyl)-L-lysyl-N-(trans-4-carbamimidamidocyclohexyl)-L-lysinamide
-
-
N2-(biphenyl-4-ylacetyl)-L-lysyl-N-[(2E)-4-carbamimidamidobut-2-en-1-yl]-L-lysinamide
-
-
N2-(biphenyl-4-ylcarbonyl)-L-lysyl-N-(2-carbamimidamidoethyl)-L-lysinamide
-
-
N2-(biphenyl-4-ylcarbonyl)-L-lysyl-N-(3-carbamimidamidopropyl)-L-lysinamide
-
-
N2-(biphenyl-4-ylcarbonyl)-L-lysyl-N-(5-carbamimidamidopentyl)-L-lysinamide
-
-
N2-(cyclohexylacetyl)-L-lysyl-L-lysinamide
N2-(phenylacetyl)-L-lysyl-L-lysinamide
N2-(phenylacetyl)-L-lysyl-L-lysine
N2-(phenylacetyl)-L-lysyl-L-lysyl-3-methylvalinamide
N2-(phenylacetyl)-L-lysyl-L-lysyl-D-alaninamide
N2-(phenylacetyl)-L-lysyl-L-lysyl-L-alaninamide
N2-(phenylacetyl)-L-lysyl-L-lysyl-L-prolinamide
N2-(phenylacetyl)-L-lysyl-L-lysyl-L-valinamide
N2-(phenylacetyl)-L-lysyl-L-lysyl-N2-methylglycinamide
N2-(phenylacetyl)-L-lysyl-L-lysylglycinamide
N2-(phenylacetyl)-L-lysyl-N-(2-aminoprop-2-en-1-yl)-L-lysinamide
N2-(phenylacetyl)-L-lysyl-N-(4-amino-4-oxobutyl)-L-lysinamide
N2-(phenylacetyl)-L-lysyl-N-(5-amino-5-oxopentyl)-L-lysinamide
N2-(phenylacetyl)-L-ornithyl-N-[(trans-4-carbamimidamidocyclohexyl)methyl]-L-lysinamide
N2-(thiophen-2-ylcarbonyl)-L-arginyl-N-[(1S)-2-amino-2-oxo-1-(4-[[4-(trifluoromethyl)benzyl]oxy]phenyl)ethyl]-L-lysinamide
the compound inhibits both unlinked and linked protease with similar potency
N2-acetyl-L-lysyl-N-(4-carbamimidamidobutyl)-L-lysinamide
-
-
N2-phenylacetyl-L-Lys-L-Lys-L-Arg-aldehyde
-
-
N2-[(2S)-4-[3-(aminomethyl)phenyl]-2-[(phenylacetyl)amino]butanoyl]-N-[(trans-4-carbamimidamidocyclohexyl)methyl]-L-lysinamide
N2-[(2S)-4-[4-(aminomethyl)phenyl]-2-[(phenylacetyl)amino]butanoyl]-N-[(trans-4-carbamimidamidocyclohexyl)methyl]-L-lysinamide
N2-[(3,4-dichlorophenyl)acetyl]-L-lysyl-N-[(1S)-1-(1-carbamimidoylpiperidin-4-yl)-2-oxoethyl]-L-lysinamide
-
-
N2-[(3,4-dichlorophenyl)acetyl]-L-ornithyl-N-[(trans-4-carbamimidamidocyclohexyl)methyl]-L-lysinamide
-
-
N2-[(3,4-dimethylphenyl)acetyl]-L-lysyl-L-lysinamide
N2-[(3,4-dimethylphenyl)acetyl]-L-lysyl-L-lysylglycinamide
N2-[(3-aminophenyl)acetyl]-L-lysyl-L-lysinamide
N2-[(4-hydroxyphenyl)acetyl]-L-lysyl-L-lysinamide
N2-[(acetylamino)(phenyl)acetyl]-L-lysyl-L-lysinamide
N2-[amino(phenyl)acetyl]-L-lysyl-L-lysinamide
N2-[[3-(aminomethyl)phenyl]acetyl]-L-lysyl-L-lysinamide
N2-[[3-(carbamimidamidomethyl)phenyl]acetyl]-L-lysyl-L-lysinamide
N2-[[4-(aminomethyl)phenyl]acetyl]-L-lysyl-L-lysinamide
N2-[[4-(carbamimidamidomethyl)phenyl]acetyl]-L-arginyl-3-methyl-L-valyl-N-(4-carbamimidoylbenzyl)-L-argininamide
N2-[[4-(carbamimidamidomethyl)phenyl]acetyl]-L-arginyl-L-arginyl-N-(4-carbamimidoylbenzyl)-L-argininamide
N2-[[4-(carbamimidamidomethyl)phenyl]acetyl]-L-arginyl-L-lysyl-N-(4-carbamimidoylbenzyl)-L-argininamide
N2-[[4-(carbamimidamidomethyl)phenyl]acetyl]-L-arginyl-L-valyl-N-(4-carbamimidoylbenzyl)-L-argininamide
N2-[[4-(carbamimidamidomethyl)phenyl]acetyl]-L-lysyl-L-lysinamide
Na2SO4
-
kosmotropic salts of the Hofmeister’s series strongly inhibit in decreasing order: sodium citrate, SO42-, acetate, Cl-
NaOAc
-
kosmotropic salts of the Hofmeister’s series strongly inhibit in decreasing order: sodium citrate, SO42-, acetate, Cl-
nona-D-Arg-amide
-
completely inhibits autolysis of the NS2B-NS3pro construct
panduratin A
phenylacetyl-Lys-Arg-Arg
phenylacetyl-Lys-Lys-Arg
phenylpropionyl-Lys-Arg-Arg
pinocembrin
-
compound from Boesenbergia rotunda (L.) Mansf. Kulturpfl.
pinostrobin
-
flavanone, non-competetive inhibitor, compound from Boesenbergia rotunda (L.) Mansf. Kulturpfl.
propionyl-Lys-Arg-Arg
propionyl-Lys-Lys-Arg
quercetin
SID-3717586
-
-
SID-4245669
-
-
SID-852843
-
-
Sodium citrate
-
kosmotropic salts of the Hofmeister’s series strongly inhibit in decreasing order: sodium citrate, SO42-, acetate, Cl-
trifluoroacetyl-Lys-Lys-Arg
[2-(2-cyanoethyl)-5-methylpyrazol-3-yl] benzoate
-
105.9% inhibition at 0.05 mM
[4-(2,3-dimethylphenyl)piperazin-1-yl]-(2-ethylsulfonyl-3,4-dihydro-1H-isoquinolin-3-yl)methanone
-
51.6% inhibition at 0.05 mM
[4-methyl-5-(3-methylbut-2-en-1-yl)-6-phenylcyclohex-3-en-1-yl](2,4,6-trimethoxyphenyl)methanone
-
-
[5-(3-methylbut-2-en-1-yl)-6-phenylcyclohex-3-en-1-yl](2,4,6-trimethoxyphenyl)methanone
-
-
[5-amino-1-(4-fluorophenyl)sulfonylpyrazol-3-yl] furan-2-carboxylate
-
107.7% inhibition at 0.05 mM
[5-amino-1-(4-fluorophenyl)sulfonylpyrazol-3-yl] thiophene-2-carboxylate
-
99.1% inhibition at 0.05 mM
[5-amino-1-(4-methoxyphenyl)sulfonylpyrazol-3-yl] 2-bromobenzoate
-
112.5% inhibition at 0.05 mM
[5-amino-1-(4-methoxyphenyl)sulfonylpyrazol-3-yl] benzoate
-
115.6% inhibition at 0.05 mM
[5-amino-1-(4-methoxyphenyl)sulfonylpyrazol-3-yl] furan-2-carboxylate
-
99.3% inhibition at 0.05 mM
[5-amino-1-(4-methoxyphenyl)sulfonylpyrazol-3-yl] thiophene-2-carboxylate
-
116.3% inhibition at 0.05 mM
[5-amino-1-(4-methylphenyl)sulfonylpyrazol-3-yl] furan-2-carboxylate
-
96.6% inhibition at 0.05 mM
[5-amino-1-(4-methylphenyl)sulfonylpyrazol-3-yl] thiophene-2-carboxylate
-
86.8% inhibition at 0.05 mM
[6-(4-methoxyphenyl)-4-methyl-5-(3-methylbut-2-en-1-yl)cyclohex-3-en-1-yl](2,4,6-trimethoxyphenyl)methanone
-
-
additional information
-